Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Aytu Biopharma (AYTU) over the last 16 years, with Sep 2025 value amounting to $32.6 million.

  • Aytu Biopharma's Cash & Current Investments rose 62.27% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.2 million, marking a year-over-year increase of 28.65%. This contributed to the annual value of $31.0 million for FY2025, which is 54.71% up from last year.
  • As of Q3 2025, Aytu Biopharma's Cash & Current Investments stood at $32.6 million, which was up 5.42% from $31.0 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Cash & Current Investments peaked at $50.2 million during Q2 2021, and registered a low of $18.2 million during Q1 2025.
  • For the 3-year period, Aytu Biopharma's Cash & Current Investments averaged around $22.2 million, with its median value being $20.0 million (2024).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 61.40% in 2022, then soared by 62.27% in 2025.
  • Over the past 5 years, Aytu Biopharma's Cash & Current Investments (Quarterly) stood at $35.3 million in 2021, then plummeted by 44.72% to $19.5 million in 2022, then climbed by 0.14% to $19.5 million in 2023, then grew by 4.45% to $20.4 million in 2024, then spiked by 62.27% to $32.6 million in 2025.
  • Its last three reported values are $32.6 million in Q3 2025, $31.0 million for Q2 2025, and $18.2 million during Q1 2025.